Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer

References

• Adkin DA, Kenyon CJ, Lerner EI, Landau I, Strauss E, Caron D, Penhasi A, Rubinstein A, Wilding IR. (1997). The use of scintigraphy to provide “proof of concept” for novel polysaccharide preparations designed for colonic drug delivery. Pharm Res, 14, 103–107.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. (2007). Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene, 26, 3473–3481.
   PubMed Web of Science ®Google Scholar
• Amselem S, Gabizon A, Barenholz Y. (1990). Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci, 79, 1045–1052.
   PubMed Web of Science ®Google Scholar
• Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators. (2006). Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med, 355, 885–895.
   PubMed Web of Science ®Google Scholar
• Arnoletti JP, Bland KI. (2006). Neoadjuvant and adjuvant therapy for rectal cancer. Surg Oncol Clin N Am, 15, 147–157.
   PubMed Web of Science ®Google Scholar
• Azab AK, Kleinstern J, Doviner V, Orkin B, Srebnik M, Nissan A, Rubinstein A. (2007). Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I -norcholesterol. J Contr Rel, 123, 116–122.
   PubMed Web of Science ®Google Scholar
• Baluom M, Friedman M, Rubinstein A. (2001). Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. J Control Release, 70, 139–147.
   PubMed Web of Science ®Google Scholar
• Bullock AN, Fersht AR. (2001). Rescuing the function of mutant p53. Nat Rev Cancer, 1, 68–76.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet, 42, 419–436.
   PubMed Web of Science ®Google Scholar
• Hagesaether E, Bye R, Sande SA. (2008). Ex vivo mucoadhesion of different zinc-pectinate hydrogel beads. Int J Pharm, 347, 9–15.
   PubMed Web of Science ®Google Scholar
• Haupt S, Haupt Y. (2006). Importance of p53 for cancer onset and therapy. Anticancer Drugs, 17, 725–732.
   PubMed Web of Science ®Google Scholar
• Haupt S, Zioni T, Gati I, Kleinstern J, Rubinstein A. (2006). Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur J Pharm Sci, 28, 204–211.
   PubMed Web of Science ®Google Scholar
• Hixon A, Crowell J. (1931). Dependent of reaction velocity upon surface and agitation. Ind Eng Chem, 23, 923–931.
   Google Scholar
• Horowitz AT, Barenholz Y, Gabizon AA. (1992). In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta, 1109, 203–209.
   PubMed Web of Science ®Google Scholar
• Johnston PG. (2006). Prognostic markers of local relapse in rectal cancer: are we any further forward? J Clin Oncol, 24, 4049–4050.
   PubMed Web of Science ®Google Scholar
• Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res, 26, 492–501.
   PubMed Web of Science ®Google Scholar
• Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948–953.
   PubMed Web of Science ®Google Scholar
• Mei X, Etzler FM, Wang Z. (2006). Use of texture analysis to study hydrophilic solvent effects on the mechanical properties of hard gelatin capsules. Int J Pharm, 324, 128–135.
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr D. (1999). Colorectal cancer. Lancet, 353, 391–399.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev, 56, 185–229.
   PubMed Web of Science ®Google Scholar
• Nadler-Milbauer MA, Azab AK, Kleinstern J, Barenholz Y. Rubinstein A. (2009). In vitro and in vivo analysis of pulsatile biodegradation of mucoadhesive hydrogels. J Drug Del Sci Tech, 19, 247–255.
   Web of Science ®Google Scholar
• O’Hagan HM, Ljungman M. (2004). Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2. Oncogene, 23, 5505–5512.
   PubMed Web of Science ®Google Scholar
• Peters MC, Isenberg BC, Rowley JA, Mooney DJ. (1998). Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed, 9, 1267–1278.
   PubMed Web of Science ®Google Scholar
• Ravizza R, Gariboldi MB, Passarelli L, Monti E. (2004). Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer, 4, 92.
   PubMedGoogle Scholar
• Richardson JC, Dettmar PW, Hampson FC, Melia CD. (2004). A simple, high throughput method for the quantification of sodium alginates on oesophageal mucosa. Eur J Pharm Biopharm, 57, 299–305.
   PubMed Web of Science ®Google Scholar
• Rubinstein A, Nakar D, Sintov A. (1992). Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content. Pharm Res, 9, 276–278.
   PubMed Web of Science ®Google Scholar
• Segal E, Pan H, Ofek P, Udagawa T, Kopecková P, Kopecek J, Satchi-Fainaro R. (2009). Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS ONE, 4, e5233.
   PubMed Web of Science ®Google Scholar
• Shangary S, Wang S. (2009). Small-molecule inhibitors of the MDM2-p53 protein- protein Interaction to reactivate p53 function: a novel approach for cancer therapy. Ann Rev Pharmacol Toxicol, 49, 223–241.
   PubMed Web of Science ®Google Scholar
• Sheng JJ, McNamara DP, Amidon GL. (2009). Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm, 6, 29–39.
   PubMed Web of Science ®Google Scholar
• Storm G, Steerenberg PA, van Borssum Waalkes M, Emmen F, Crommelin DJ. (1988). Potential pitfalls in in vitro antitumor activity testing of free and liposome-entrapped doxorubicin. J Pharm Sci, 77, 823–830.
   PubMed Web of Science ®Google Scholar
• Sun W, Haller DG. (2005). Adjuvant therapy of colon cancer. Semin Oncol, 32, 95–102.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844–848.
   PubMed Web of Science ®Google Scholar
• Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bünte H. (1995). Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose non-steroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum, 38, 813–830.
   PubMed Web of Science ®Google Scholar
• Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L. (2010). Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol, 136, 1597–1604.
   PubMed Web of Science ®Google Scholar